Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder

Roberta A. Kowatch, Trisha Suppes, Thomas J. Carmody, John P. Bucci, Judith H. Hume, Michelle Kromelis, Graham J. Emslie, Warren A. Weinberg, A. John Rush

Research output: Contribution to journalArticle

299 Citations (Scopus)

Abstract

Objective: To develop effect sizes for 3 mood stabilizers - lithium, divalproex sodium, and carbamazepine - for the acutephase treatment of bipolar I or II disorder, mixed or manic episode, in children and adolescents aged 8 to 18 years. Method: Forty-two outpatients with a mean age of 11.4 years (20 with bipolar I disorder and 22 with bipolar II disorder) were randomly assigned to 6 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly Clinical Global Impression Improvement scores and the Young Mania Rating Scale (Y-MRS). Results: Using a ≥50% change from baseline to exit in the Y-MRS scores to define response, the effect size was 1.63 for divalproex sodium, 1.06 for lithium, and 1 00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were as follows: sodium divalproex, 53%; lithium, 38%; and carbamazepine, 38% (χ 2 2 = 0.85, p = 60). All 3 mood stabilizers were well tolerated, and no serious adverse effects were seen. Conclusions: Divalproex sodium, lithium, and carbamazepine an showed a large effect size in the open treatment of children and adolescents with bipolar I or II disorder in a mixed or manic episode.

Original languageEnglish (US)
Pages (from-to)713-720
Number of pages8
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume39
Issue number6
StatePublished - 2000

Fingerprint

Carbamazepine
Valproic Acid
Bipolar Disorder
Lithium
Outpatients
Therapeutics

Keywords

  • Bipolar disorder
  • Carbamazepine
  • Divalproex sodium
  • Effect size
  • Lithium

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. / Kowatch, Roberta A.; Suppes, Trisha; Carmody, Thomas J.; Bucci, John P.; Hume, Judith H.; Kromelis, Michelle; Emslie, Graham J.; Weinberg, Warren A.; Rush, A. John.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 39, No. 6, 2000, p. 713-720.

Research output: Contribution to journalArticle

Kowatch, Roberta A. ; Suppes, Trisha ; Carmody, Thomas J. ; Bucci, John P. ; Hume, Judith H. ; Kromelis, Michelle ; Emslie, Graham J. ; Weinberg, Warren A. ; Rush, A. John. / Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2000 ; Vol. 39, No. 6. pp. 713-720.
@article{826d097be39440bfa7d3112c2dcdfc13,
title = "Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder",
abstract = "Objective: To develop effect sizes for 3 mood stabilizers - lithium, divalproex sodium, and carbamazepine - for the acutephase treatment of bipolar I or II disorder, mixed or manic episode, in children and adolescents aged 8 to 18 years. Method: Forty-two outpatients with a mean age of 11.4 years (20 with bipolar I disorder and 22 with bipolar II disorder) were randomly assigned to 6 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly Clinical Global Impression Improvement scores and the Young Mania Rating Scale (Y-MRS). Results: Using a ≥50{\%} change from baseline to exit in the Y-MRS scores to define response, the effect size was 1.63 for divalproex sodium, 1.06 for lithium, and 1 00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were as follows: sodium divalproex, 53{\%}; lithium, 38{\%}; and carbamazepine, 38{\%} (χ 2 2 = 0.85, p = 60). All 3 mood stabilizers were well tolerated, and no serious adverse effects were seen. Conclusions: Divalproex sodium, lithium, and carbamazepine an showed a large effect size in the open treatment of children and adolescents with bipolar I or II disorder in a mixed or manic episode.",
keywords = "Bipolar disorder, Carbamazepine, Divalproex sodium, Effect size, Lithium",
author = "Kowatch, {Roberta A.} and Trisha Suppes and Carmody, {Thomas J.} and Bucci, {John P.} and Hume, {Judith H.} and Michelle Kromelis and Emslie, {Graham J.} and Weinberg, {Warren A.} and Rush, {A. John}",
year = "2000",
language = "English (US)",
volume = "39",
pages = "713--720",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder

AU - Kowatch, Roberta A.

AU - Suppes, Trisha

AU - Carmody, Thomas J.

AU - Bucci, John P.

AU - Hume, Judith H.

AU - Kromelis, Michelle

AU - Emslie, Graham J.

AU - Weinberg, Warren A.

AU - Rush, A. John

PY - 2000

Y1 - 2000

N2 - Objective: To develop effect sizes for 3 mood stabilizers - lithium, divalproex sodium, and carbamazepine - for the acutephase treatment of bipolar I or II disorder, mixed or manic episode, in children and adolescents aged 8 to 18 years. Method: Forty-two outpatients with a mean age of 11.4 years (20 with bipolar I disorder and 22 with bipolar II disorder) were randomly assigned to 6 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly Clinical Global Impression Improvement scores and the Young Mania Rating Scale (Y-MRS). Results: Using a ≥50% change from baseline to exit in the Y-MRS scores to define response, the effect size was 1.63 for divalproex sodium, 1.06 for lithium, and 1 00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were as follows: sodium divalproex, 53%; lithium, 38%; and carbamazepine, 38% (χ 2 2 = 0.85, p = 60). All 3 mood stabilizers were well tolerated, and no serious adverse effects were seen. Conclusions: Divalproex sodium, lithium, and carbamazepine an showed a large effect size in the open treatment of children and adolescents with bipolar I or II disorder in a mixed or manic episode.

AB - Objective: To develop effect sizes for 3 mood stabilizers - lithium, divalproex sodium, and carbamazepine - for the acutephase treatment of bipolar I or II disorder, mixed or manic episode, in children and adolescents aged 8 to 18 years. Method: Forty-two outpatients with a mean age of 11.4 years (20 with bipolar I disorder and 22 with bipolar II disorder) were randomly assigned to 6 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly Clinical Global Impression Improvement scores and the Young Mania Rating Scale (Y-MRS). Results: Using a ≥50% change from baseline to exit in the Y-MRS scores to define response, the effect size was 1.63 for divalproex sodium, 1.06 for lithium, and 1 00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were as follows: sodium divalproex, 53%; lithium, 38%; and carbamazepine, 38% (χ 2 2 = 0.85, p = 60). All 3 mood stabilizers were well tolerated, and no serious adverse effects were seen. Conclusions: Divalproex sodium, lithium, and carbamazepine an showed a large effect size in the open treatment of children and adolescents with bipolar I or II disorder in a mixed or manic episode.

KW - Bipolar disorder

KW - Carbamazepine

KW - Divalproex sodium

KW - Effect size

KW - Lithium

UR - http://www.scopus.com/inward/record.url?scp=0034034183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034034183&partnerID=8YFLogxK

M3 - Article

C2 - 10846305

AN - SCOPUS:0034034183

VL - 39

SP - 713

EP - 720

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 6

ER -